Mental Health Clinics in Fairlawn, NJ Accepting Medicare
3 Mental Health Clinics found. Showing 1 - 3
 Hudson Arts And Science Charter Schools Psychologist Medicare: Not Enrolled in Medicare Practice Location: 33-00 Broadway, Fairlawn, NJ 07410 Phone: 201-773-9140 |
Bergen Arts And Science Charter Schools Psychologist Medicare: Not Enrolled in Medicare Practice Location: 33-00 Broadway, Fairlawn, NJ 07410 Phone: 201-773-9140 |
Jennifer Stefanik, Lcsw, Llc Social Worker - Clinical Medicare: Medicare Enrolled Practice Location: 0-55 34th St, Fairlawn, NJ 07410 Phone: 201-686-0871 |
News Archive
New method to predict risk of breast cancer
Mayo Clinic researchers have found that certain structural features within breast tissue can indicate a woman's individual cancer risk. The findings appear online today in the Journal of Clinical Oncology.
Eye abnormalities may help reveal features of early-stage Alzheimer's disease, says study
​Investigators at the Cedars-Sinai Regenerative Medicine Institute have discovered eye abnormalities that may help reveal features of early-stage Alzheimer's disease. Using a novel laboratory rat model of Alzheimer's disease and high-resolution imaging techniques, researchers correlated variations of the eye structure, to identify initial indicators of the disease.
Survey shows negative effect of vulvovaginal atrophy symptoms on quality of life for women
With symptoms such as dryness, burning, or itching of the vagina, vulvovaginal atrophy is estimated to affect up to 98% of postmenopausal women, many of whom will fail to report symptoms to their healthcare providers or seek help.
Australian company receives FDA orphan drug designation for product to treat malignant melanomas
Progen Industries Limited, an Australian anti-cancer drug development company, announced today that it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for their lead anti-angiogenesis product PI-88 for treatment of malignant melanoma.
Abstract on ACH-1625 accepted as late breaking poster presentation at The Liver Meeting 2010
Achillion Pharmaceuticals, Inc., a leader in the discovery and development of treatments for the most challenging infectious diseases, today announced that its abstract titled "ACH-1625 Demonstrates Sustained Viral Suppression in Presence of Uncommon Drug Resistant HCV Variants: Pharmacokinetic, Pharmacodynamic and Clinical Virology Analysis of Phase I Study" has been accepted as a late breaking poster presentation at the 61st Annual Meeting of the American Association for the Study of Liver Disease The Liver Meeting 2010 being held October 29-November 2, 2010 in Boston.
› Verified 2 days ago